MedTrace Logo

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

NCT00288444 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2012-12-18

No results posted yet for this study

Summary

To determine the molecular interaction in tumor samples between docetaxel and lonafarnib.

Conditions

Interventions

DRUG

Lonafarnib

DRUG

Docetaxel

Sponsors & Collaborators

  • Aventis Pharmaceuticals

    collaborator INDUSTRY

  • Schering-Plough

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • John Kauh, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-05-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00288444 on ClinicalTrials.gov